| Oct 22 |
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
|
| Sep 11 |
Alto Neuroscience Insiders Placed Bullish Bets Worth US$638.5k
|
| Sep 5 |
15 Healthiest Countries in Asia
|
| Sep 4 |
Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants
|
| Sep 3 |
Alto Neuroscience to Participate in Upcoming Investor Conferences
|
| Aug 14 |
Alto Neuroscience GAAP EPS of -$0.60
|
| Aug 13 |
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights
|
| Aug 1 |
institutional investors of Alto Neuroscience, Inc. (NYSE:ANRO) must be disappointed after last week's 26% drop
|
| Jul 30 |
IPO Roundup: Pershing Square, Actuate Therapeutics and more
|
| Jul 28 |
Wall Street Breakfast: The Week Ahead
|
